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Gangliosides are integral to the structure and function of cell membranes. Ganglioside composition of the intestinal brush border
and apical surface of the colon inﬂuences numerous cell processes including microbial attachment, cell division, diﬀerentiation,
and signaling. Accelerated catabolism of ganglioside in intestinal disease results in increased proinﬂammatory signaling. Restoring
proper structure and function to the diseased intestine can resolve inﬂammation, increase resistance to infection, and improve gut
integrity to induce remission of conditions like necrotizing enterocolitis (NEC) and Crohn’s disease (CD). Maintaining inactive
state of disease may be achieved by reducing the rate that gangliosides are degraded or by increasing intake of dietary ganglioside.
Collectively, the studies outlined in this paper indicate that the amount of gangliosides GM3 and GD3 in intestinal mucosa is
decreased with inﬂammation, low level of GM3 is associated with higher production of proinﬂammatory signals, and ganglioside
content of intestinal mucosa can be increased by dietary ganglioside.
1. Review
Ganglioside refers to a network of sialylated glycosph-
ingolipids, each with independent biologic properties
(Figure 1)[ 1–3]. Gangliosides are found mainly in the
lipid rafts of the intestinal mucosa [4]. Gangliosides consist
of a charged, hydrophilic region that protrudes from the
membrane surface, and a hydrophobic ceramide anchored in
the cell membrane [5].
1.1. Ganglioside Synthesis and Degradation. In mammalian
cells, ganglioside synthesis commences with ceramide syn-
thesis in the endoplasmic reticulum [7, 8]. Ceramide is
transportedtothecytosolicGolgifaceforadditionofglucose
[9]. From this point, sugar moieties and sialic acids are
added to form one of several gangliosides. These reactions
are accomplished by sialyltransferases, galactosaminyltrans-
ferases, and galactosyltransferases on the luminal face of
the Golgi complex at controlled rates [10]. Ganglioside
catabolism is outlined in Figure 2.
1.2. Ganglioside Content and Composition. The amount and
content of ganglioside varies among species and in tissues
within species [12]. Transcriptional and posttranslational
eventsregulatetheamountandcontentofgangliosideincells
[13]. Ganglioside content is particularly high in the central
nervoussystem,relativetoothertissuesofthebody[14].The
fattyacidtailofceramidealsovariesinlengthwithinganglio-
sides [15],asdemonstratedinA2780 ovarian carcinomacells
[16]. Variability in sialic acid conﬁguration, oligosaccharide
size, and length of ceramide may have consequences that
alter ganglioside localization and functionality [17–19]. It
is unknown whether many of the health beneﬁts attributed
to gangliosides are due to a speciﬁc ganglioside species like
GM3 or GD3, or whether the fatty acid component of the
ceramide tail alters the molecular role of the ganglioside.
2.GangliosideinDiet
In addition to endogenous ganglioside biosynthesis, gan-
glioside can also be obtained exogenously from diet [20].2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 1:Generalschemeforgangliosidesynthesis.Networkofgangliosidesynthesis;stepsarealsoreversible.“G”denotes“ganglioside;”“A”
denotes “asialo” or lacking sialic acid; “M” denotes “monosicalo,” “D” denotes “disialo;” numbers denote carbohydrate sequence. Adapted
from Malisan and Testi [6]. Cer: ceramide; GlcCer: glucosylceramide; LacCer: lactosylceramide; GalNac: N-acetylgalactosamine.
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Figure 2: Ganglioside catabolism. Enzyme responsible for catabolic processing step is shown adjacent to arrow. Adapted from Devlin [11].
The milk fat globule membrane is a biological membrane
enriched in ganglioside that protects and stabilizes milk fat
in the aqueous phase [21]. Dietary ganglioside intake is very
low unless consuming whole-organ foods (i.e., brain), whole
milk, buttermilk, or colostrum in high quantities. Several
tissues have been shown to incorporate dietary gangliosides.
Caco-2 cells incorporate GD3 [22] when provided with
ganglioside in vitro [23]. Ganglioside uptake also occurs
in several tissues in vivo. Providing ganglioside in the diet
increases ganglioside content in intestinal mucosa [20]. Pro-
viding GM3 and GD3 in the diet increased total ganglioside
content of epithelial cells within intestine and retina in rats
[20, 24]. The estimated average intake of ganglioside in
a healthy population is well below levels believed to bear
therapeutic beneﬁt [25].
2.1. Fatesof DietaryGanglioside. GD3is speciﬁcallylocalized
to the basolateral membrane surface, while GM3 is localized
at the brush border membrane of the enterocyte [26].
According to Pagano’s vesicle sorting theory [27], absorbed
gangliosides have three fates: transport back to the plasma
membrane immediately after being endocytosed; endocyto-
sis to the Golgi apparatus for glycosylation to form more
complex ganglioside species; transport by the endosome to
the lysosome for degradation. Metabolic kinetics of GD3
has been described in depth in Caco-2 cells. GD3 taken up
by the brush border membrane is mainly metabolized into
newgangliosidespecies,withsmallerportionsbeingretained
or transferred, whereas GD3 taken up by the basolateral
membrane is not retained or transferred to any signiﬁcant
degree [22]. These observations suggest that each species ofJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
gangliosidelocalizestoparticularregionsoftheenterocyteto
carry out speciﬁc functions, which depend on site of uptake.
Thereisagapinunderstandingofhowgangliosideuptakeby
diﬀerent cell types and regions of the gut is regulated.
2.2. Ganglioside in Intestinal Health. Important observations
from animal studies show that inﬂamed intestinal mucosa
has less ganglioside content than healthy intestinal mucosa
[28]. Dietary ganglioside is able to replace mucosal gan-
gliosides that are continually degraded in inﬂammatory
states. Moreover, increasing ganglioside content through diet
decreases proinﬂammatory cytokine production in intesti-
nal mucosa [24, 28] and prevents hypoxia-induced bowel
necrosis and cell injury in cultured infant bowel [29]. The
following section summarizes the diﬀerent modes of action
by which dietary gangliosides promote intestinal health.
3. Mechanisms of Action of Ganglioside
3.1. Gut Integrity. Previous studies indicate that ganglioside
prevents proinﬂammatory stimuli from disrupting integrity
of tight junctions between enterocytes. Feeding ganglioside
to rats prevented a lipopolysaccharide- (LPS-) stimulated
decrease in cellular tight junction protein occludin [30].
This work indicates that low levels of GM3 in the intestinal
mucosa are associated with degradation of tight junction
proteins. Improving intestinal integrity is important for
management of diarrhea, infection, penetration of allergens,
and malnutrition. Guanylate-binding protein-1 (GBP-1) has
been recently identiﬁed as a marker of intestinal integrity.
Downregulation of GBP-1 has been reported to increase
permeability and apoptosis of intestinal cells [31]. The eﬀect
of ganglioside on GBP-1 stability is currently unknown and
is of interest as a potential therapeutic target.
3.2. Immune Cell Targeting. Chemokine receptor type 9
(CCR9) enables immune cells to target the gut [32]. While
CCR9-positive immune cells are found mainly in small
intestine, integrin α4β7-positive cells tend to home to both
small intestine and colon [33]. Integrin-mediated binding
may be indirectly inﬂuenced by ganglioside. In the plasma
membrane, gangliosides are known to localize with proteins
whichbearspeciﬁcaminoacidsequences[34].GD3hasbeen
shown to cluster with β1 integrin and aﬀect properties con-
trolledbyintegrin-mediatedsignalling[35].Theinteractions
between gangliosides and integrins have not received much
attention, but may provide important insights into homing
ofimmunecellstogutinconditionslikeinﬂammatorybowel
disease (IBD).
3.3. Immune Cell Signaling. Gangliosides are organized into
microdomains termed lipid rafts that ﬂoat freely in the lipid
bilayer [36] and serve as organizing centers for assembly
of signaling molecules and receptor traﬃcking [37, 38].
Organization of signaling molecules into lipid rafts is vital
for regulation of T-lymphocyte activation pathways that play
a major role in pathology of IBD [39, 40]. Disruption of
lipid rafts displaces cellular signaling molecules and alters
immunoreceptor signal transduction [41–43]. Speciﬁcally,
sphingolipid depletion inhibits glycophosphatidylinositol-
anchored protein traﬃcking in microdomains [44]. Absence
or increased catabolism of ganglioside adversely aﬀects lipid
raft traﬃcking and signaling functions and promotes an
inﬂammatory environment. Gangliosides are imperative for
proper structure and function of lipid rafts and dietary gan-
glioside may disrupt constitutive activation of inﬂammatory
pathways that are hallmark of intestinal disease.
3.4. Proinﬂammatory Mediators. Inﬂammation characterizes
several chronic diseases including cardiovascular disease,
cancer,NEC,andIBD.Inculture,inﬂamedintestinalmucosa
hassigniﬁcantlydecreasedgangliosidecontent[28].Changes
in ganglioside content and composition also occur in the
oncogenic transformation of tissue. Undiﬀerentiated Caco-
2 cells have lower total GD3 and polar gangliosides than
diﬀerentiated Caco-2 model intestinal epithelial cells [45].
It is unknown whether ganglioside catabolism precedes the
proinﬂammatory signals and subsequent inﬂamed state,
or whether inﬂammation induces ganglioside catabolism.
Enrichment of intestinal mucosa with ganglioside causes a
reduction in cholesterol content [28]. Cholesterol depletion
disrupts membrane microdomain structure and inhibits
generation of proinﬂammatory mediators [46, 47]. In pre-
clinical studies, ganglioside treatment increases ganglioside
content and inhibits signals caused by proinﬂammatory
stimuli tumour necrosis factor-α and interleukin- (IL-) 1β
in rats [28]. Similarly, ganglioside reduces IL-6 and IL-8
production in cultured infant bowel when exposed to LPS
under hypoxic conditions [29]. Replacing ganglioside that is
degraded protects the gut by attenuating proinﬂammatory
signals.
3.5. Anti-Inﬂammatory Mediators. Previous studies have
shown enhanced production of IL-10 with dietary ganglio-
side treatment [30]. IL-10 is an anti-inﬂammatory cytokine
and may be involved in resolution of inﬂammation. Polyun-
saturated docosahexaenoic-acid-derived resolvins and pro-
tectins have recently been discovered as having anti-
inﬂammatory properties [48]. Production of resolvin D3
and protectin 1/D1 may be responsible for blocking dextran
sodium sulfate-induced colitis in mice [49]. Therefore,
resolvins and protectins have been suggested as novel candi-
dates for IBD therapy [50]. Ganglioside in the diet increases
the amount of polyunsaturated fat relative to saturated fat in
weanling rat intestine [51] and, thus, may enable enhanced
production of resolvins and protectins.
3.6. Prevention of Infection. Provision of dietary ganglio-
side known to have antibacterial properties increases the
resistance of an individual to negative eﬀects of microbial
pathogens. Evidence suggests that patients with IBD may
be more prone to infection than healthy individuals [52].
In a Spanish population, mutation in authophagy related
16-like 1 (ATG16L1) is associated with prevalence of CD
[53] .A T G 1 6 L 1i sp a r to fag r o u po fp r o t e i n si n v o l v e d
in autophagy [54] .D e f e c t si nA T G 1 6 L 1m a ya l l o wf o r4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 3: Inﬂammatory signaling cascade and mechanisms by
which ganglioside protects the intestine from inﬂammation and
injury. There are at least four possible mechanisms by which
ganglioside protects intestine from injury: (1) gangliosides prevent
proliferation, maturation and targeting of immune cells; (2) gan-
gliosides bind enterotoxic LPS and prevent interaction with TLR4;
(3) gangliosides inhibit NFκB activation; and (4) gangliosides
prevent production of LTB4 and PGE2. Adapted from Schnabl et al.
[29]. COX-2 = cyclooxygenase-2; cPLA2 = cytosolic phospholipase
A2; LTB4 = leukotriene B4;L P S= lipopolysaccharide; 5 LOX = 5
lipoxygenase; PGE2 = prostaglandin E2;P L= phospholipid; ROS =
r e a c t i v eo x y g e ns p e c i e s ;1 ,2 ,3 ,4= steps inhibited by ganglioside;
TLR4 = toll-like receptor-4.
infectious organisms to persist, triggering an exacerbated
immune response in the gut. Toll-like receptor-4 (TLR4)
was found to be higher in intestinal mucosa of children
with IBD than healthy controls [55]. Upon stimulation
of TLR4 by pathogens or enterotoxins (Figure 3), immune
cells produce reactive oxygen species that lead to activation
of nuclear transcription factor-kappaB (NFκB) pathway
and production of inﬂammatory mediators. Ganglioside
inhibits binding, toxin production, and infectivity of several
intestinal pathogens [56, 57], thereby attenuating NFκB
inﬂammatory signaling pathways. Ganglioside may play a
criticalroleinsupportingguthealthbypreventingsecondary
infection and the associated inﬂammatory signaling cascade.
3.7. NFκBP a t h w a y .CARD15 (nucleotide-oligomerization
domain-containing protein 2 (NOD2)) polymorphism has
most consistently arisen as a genetic risk factor for CD
[58, 59]. The normal function of CARD15 is to suppress
NFκB stimulation [60]. Defects in CARD15 allow constitu-
tive activation of NFκB, resulting in chronic inﬂammation
and injury to intestinal mucosa. Nucleotide-oligomerization
domain-containing protein 1 (NOD1) is an activator of
NFκB and wild-type NOD1 is associated with increased risk
of CD [61]. Ganglioside may attenuate NFκB signaling as
a previous study showed that GD3 prevented activation of
NFκB in mitogen-stimulated T cells [62]. This is particularly
important since cyclooxygenase (COX) and lipoxygenase
(LOX) enzyme production is increased by stimulation of
NFκBp a t h w a y[ 63]. COX and LOX metabolize arachidonic
acid (AA) into proinﬂammatory mediators leukotriene B4
(LTB4) and prostaglandin E2 (PGE2). It has been shown that
ganglioside prevents production of LTB4 and PGE2 in infant
bowel when cultured with LPS [29]. Ganglioside appears to
inhibitproductionofLTB4 andPGE2 inintestinebyblocking
nuclear translocation of NFκB[ 64].
4. IBD Background
Ganglioside has shown therapeutic beneﬁt in models of
proinﬂammatory diseases that have common features with
IBD. Collectively known as IBD, CD and ulcerative colitis
(UC) severely impede quality of life in aﬄicted individuals.
IBD presents with abdominal pain, gastrointestinal bleed-
ing, diarrhea, weight loss, and malnutrition; all of which
negatively impact social and emotional welfare. IBD can
be associated with development of joint, liver, and kidney
diseases, and an elevated risk of lymphoma and colorectal
cancer. Disease management is diﬃcult and may consist
of costly drug treatment including steroids, immunosup-
pressants [65], or antibiotics [66]. Some individuals with
IBD do not respond to standard drug treatment, while
others experience negative or toxic adverse eﬀects [67].
Administration of prednisolone has been shown as a risk
factor for development osteoporosis in older patients with
IBD [68]. Severe cases require surgery to remove the aﬀected
bowel, and psychological factors including stress may trigger
disease ﬂares [69]. The etiologies of CD and UC are poorly
understood and there is no cure for IBD.
4.1. IBD Epidemiology. At a rate of 0.60% of the population
[70], prevalence of IBD is particularly high in Canada [71]
compared to the rest of the world [72–74]. Prevalence
of IBD is also high in the United States, where reported
incidence is approximately 1.1 million people per year
[72]. IBD is a considerable economic burden. In 2008,
economic cost per patient with IBD was estimated above
$9,000/year in Canada [70]. Another study reported direct
healthcare costs greater than $18,000/patient-year in the
United States [75]. There is a clear need for knowledge of
diseasemechanismstodevelopnovelcost-eﬀectivetreatment
strategies for sustained remission of disease.
4.2. IBD Pathology. CD is chronic enteritis that can occur
at any site along the gastrointestinal tract. Initial lesions are
characterizedbytinymucosaldefectstermedaphthousulcers
[76]. There is an inﬁltration of macrophages that release
proinﬂammatory mediators and perpetuate the inﬂam-
matory process. This process contributes to development
of ﬁbrotic bands and granulomas. Ulcers grow in size
and, as submusoca thickens, ﬁstulae may develop. While
inﬂammation associated with CD occurs in a transmural
fashion in the colonic wall, UC-associated inﬂammationJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
is present superﬁcially at the level of mucosa [77]. With
r e s p e c tt oi m m u n es y s t e mi n v o l v e m e n t ,U Ci sc h a r a c t e r i z e d
by Th1c e l l sa n dC Db yT h2, Th17, and cells involved
in innate immunity. There is a strong genetic component
that contributes to IBD risk, particularly CD [78]. While
a number of genes have been linked to aspects of IBD,
environmentalsoplaysalargeroleinactivedisease.IBDrates
are very high in industrialized countries like Canada and
the USA. Studies have linked urban environment, smoking,
diet high in sugar or total fat, antibiotic use in childhood,
nonsteroidal anti-inﬂammatory use, and many other factors
to IBD risk [79]. IBD is a multifactorial disorder of complex
origin that appears to stem from changes initially occurring
at the cell membrane.
4.3. Ganglioside in IBD Pathology. Ganglioside species com-
positions diﬀer among several disease states. For example,
Sandhoﬀ’s, Gaucher, and Tay Sach’s diseases are charac-
terized by abnormal sphingolipid metabolism due to gene
deﬁciencies for catabolic enzymes and accumulation of gan-
gliosides[80]. A few studies have delved into the relationship
betweengenesthatregulategangliosidemetabolismandIBD.
A genetic variant of lysosomal sialidase is associated with
CD [81], but this study did not assess whether ganglioside
content correlates with sialidase genotype. Another study
showed that there was no diﬀerence in β-galactosidase
enzyme activity between LPS-stimulated mononuclear cells
from IBD patients and healthy controls [82]. In the same
study, β-hexosaminidase enzyme activity was higher in
peripheral blood monocytes of patients with IBD than in
healthy control subjects when incubated with LPS. Since
β-hexosaminidase generates GM3 from GM2, accelerated
ganglioside catabolism contributes to pathogenesis of IBD.
5. Conclusions
IBD is a disorder inﬂuenced by many environmental and
genetic factors. Signs regularly present in individuals with
IBD include chronic inﬂammation, overactive immune
response, and impaired integrity and permeability of gut.
While signs and symptoms may subside for short periods
of time, recurrence of IBD-related episodes is regular.
There is appreciable cost associated with treating IBD. As
surgical intervention or drug administration does not result
in a cure, there is demand for new treatment initiatives.
Emerging evidence shows the critical role of ganglioside in
supporting intestinal health. Ganglioside metabolism in the
intestinal mucosa is fundamental to the etiology of IBD.
Studies show that low levels of ganglioside in the intestinal
mucosa are associated with increased levels of inﬂammatory
markers, susceptibility to pathogens, and poor gut integrity.
Dietary ganglioside constitutes an exciting new therapeutic
agent which targets intestinal cells and associated immune
surveillance by interrupting the inﬂammatory cascade and
subsequently alleviating signs and symptoms of inﬂamma-
tory intestinal diseases. Dietary ganglioside consumption
alleviates many of the burdensome processes in models of
intestinaldiseasethatarealsocharacteristicofIBDand,thus,
may provide beneﬁt to aﬄicted individuals.
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